Algorae Pharmaceuticals Advances Dementia Drug AI-116
Company Announcements

Algorae Pharmaceuticals Advances Dementia Drug AI-116

Living Cell Technologies Ltd. (AU:1AI) has released an update.

Algorae Pharmaceuticals Limited has reported promising pre-clinical results for AI-116, a drug candidate aimed at treating dementia, which demonstrated a significant reduction in glutamate-induced toxicity, outperforming the existing FDA-approved drug Donepezil. The company has also identified unique gene modulations associated with neurodegenerative disorders following AI-116 treatment, and has initiated the process for an international patent while planning for upcoming clinical trials.

For further insights into AU:1AI stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskLiving Cell Technologies Announces Director’s Interest Change
TipRanks Australian Auto-Generated NewsdeskAlgorae Pharmaceuticals Plans Major Securities Issuance
TipRanks Australian Auto-Generated NewsdeskAlgorae Pharmaceuticals Secures Shareholder Support at AGM
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App